Wow! Tamiflu to the rescue! Is there anything it can’t do?
- Roche announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) extending the prophylaxis (prevention) indication for TamifluÂ® (oseltamivir phosphate) to include children ages one through 12. The leading prescription antiviral medication for prevention and treatment of influenza, Tamiflu was previously approved for prophylaxis in adolescents (age 13 years and older) and adults. Tamiflu is also the only antiviral medication indicated for the treatment of influenza type A or type B infection in patients one year and older, and is available in both capsule and liquid suspension formulations.